Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level

作者：Irl B. Hirsch, Yogish C. Kudva, David Ahn, Thomas Blevins, Michael R. Rickels, Dan Raghinaru, John W. Lum, Craig Kollman, Jordan E. Pinsker, Roy W. Beck, 2IQP Study Group*, Yogish C. Kudva, Donna Desjardins, Corey Kurek, Ravinder Jeet Kaur, Daine Livingood, Shafaq Rizvi, Timothy E. Graham, Adrienne Terry, Ryan Luker, Melanie Mellenthin, Stephanie Rezac, David R. Liljenquist, Justin Rogers, Joshua W. Smith, Jonathan Williams, Rochelle Christensen, In‐Kyoung Lee, Joann Malone, Elias K. Spanakis, Lakshmi G. Singh, Jade Churchill, Kathleen Comen, William H. Scott, Francisco J. Pasquel, Georgia M. Davis, Farbod Zahedi Tajrishi, Lizda Guerrero Arroyo, Omolade Oladejo, Sabeena Usman, Andrew Ahmann, Caleb Schmid, Ariel Dean, Deborah Branigan, Brittany Caswell, Matthew O. Howard, Tess Heyerman, Brian Tessman, Jnh Vanderheide, David Ahn, Brittany Dennis, Lisa Hendricks, Clemente Reyes-Rodriguez, Valerie Wolf, Grazia Aleppo, Kasey Coyne, Jelena Kravarusic, Evelyn Fronczyk, Stefanie Herrmann, Samsam C. Penn, Thomas Blevins, Luis Casaubon, Valerie Espinosa, Keta Pandit, Jennifer Perez, Ana Stewart, Courtney Assir, Cory Fields, Davida Kruger, Kathleen Estrada, J. Kimberly Jones, Shereen Mukhashen, Natalie Corker, Heather Hunter, Paula Layton, Sue A. Brown, Samina Afreen, Jasmeen Dhillon, Emma Emory, David Fulkerson, Morgan Fuller, Viola Holmes, Laura Kollar, Mary Oliveri, Elyse Toole, Carol J. Levy, Camilla Levister, Grenye O’Malley, Aslihan Ipek, Denise Alabi, Emily Ellis, Shaziah Hassan, Selassie Ogyaadu, Denisa Tamarez, Ruth S. Weinstock, Sheri Stone, Suzan Bzdick, Lynn Agostini, Jane Bulger, Devin Steenkamp, Howard Wolpert, Astrid Atakov-Castillo, Asya Sullivan, Corinne Aia, Elizabeth Brouillard, Tamara Spaic, Selina Liu, Marsha Driscoll, Heather Lapier, Sherryl Payra, Louise Vancer, Irl B. Hirsch, Xenia Averkiou, Jesica Baran, Rosanna Holod, Patrisia Litvicov, Patali Mandava, Sydney Swinton, Dori Khakpour, Frances E. Broyles, Sheryl Marks, Tina Mitchell, Babette Hairston, Reilly Costello, Stella Curtis, Michael R. Rickels, Jorge Jo Kamimoto, Amy J. Peleckis, Rahaf Sultan, Cornelia Dalton-Bakes, Patricia Bourne, Michael A. Tsoukas, Ahmad Haidar, Melissa Pasqua, Vanessa Tardio, Adelyn Moore, Gabrielle Kemp, Philip Raskin, L.F. Jordan, Baomei Shao, Trang DoNguyen, Tram Meeks, Michael Phan, Betül Hatipoğlu, Amanda Lesniak, Mario Becerra, Natalie J. Bellini, Erica Denallo, Quiana Howard, Claudia Lewis, Jerry Tribout, Megan Tribout, Kathryn DiFrancesco, Kylie Phillips, John W. Lum, Dan Raghinaru, Tiffany Campos, Beth Morrell, Vanessa Oduah, Gabriela Cardenas-Villamil, Amanda Morales, Carlos Murphy, Heidi Strayer, Charles Spanbauer, Lauren Kanapka, Craig Kollman, Roy W. Beck, Jordan E. Pinsker, Ravid Sasson-Katchalski, Nicole Piquette, Alex Wheatcroft, KIRSTIN N. WHITE, KC Carmelo, Robert Janicek, Deanna Gabrielson, Hung V. Le, Kevin Mercado · 发表于：Diabetes Care · 年份：2025 · DOI：10.2337/dc25-1125 · 被引用次数：6 · 研究领域：Diabetes and associated disorders、Diabetes Management and Research、Pancreatic function and diabetes

OBJECTIVE: The Centers for Medicare & Medicaid Services (CMS) requires a low C-peptide level for insulin pump coverage unless the individual is β-cell autoantibody positive, which precludes coverage of automated insulin delivery (AID) systems for many people with type 2 diabetes. RESEARCH DESIGN AND METHODS: In the Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy study evaluating the t:slim X2 insulin pump with Control-IQ+ technology, adults with insulin-treated type 2 diabetes were categorized into high C-peptide (n = 195) and low C-peptide (n = 59) groups based on CMS criteria. RESULTS: In the AID group, mean HbA1c decreased from baseline by 0.8%, which was significantly greater than in the control group with both high (P < 0.001) and low (P = 0.02) C-peptide levels. Results were similar in participants ≥65 years old. CONCLUSIONS: The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted.